Synthaverse S.A.

WSE:SVE Lagerbericht

Marktkapitalisierung: zł307.1m

Synthaverse Management

Management Kriterienprüfungen 1/4

Wir verfügen derzeit nicht über ausreichende Informationen über den CEO.

Wichtige Informationen

Mieczyslaw Starkowicz

Geschäftsführender

n/a

Gesamtvergütung

Prozentsatz des Geschäftsführergehaltsn/a
Amtszeit als Geschäftsführer2.3yrs
Eigentum des Geschäftsführers0.2%
Durchschnittliche Amtszeit des Managementskeine Daten
Durchschnittliche Amtszeit der Vorstandsmitglieder3.3yrs

Jüngste Management Updates

Recent updates

Optimistic Investors Push Synthaverse S.A. (WSE:SVE) Shares Up 32% But Growth Is Lacking

Apr 20
Optimistic Investors Push Synthaverse S.A. (WSE:SVE) Shares Up 32% But Growth Is Lacking

Why Synthaverse's (WSE:SVE) Soft Earnings Are Just The Beginning Of Its Problems

Apr 18
Why Synthaverse's (WSE:SVE) Soft Earnings Are Just The Beginning Of Its Problems

BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek (WSE:BML) Seems To Use Debt Quite Sensibly

Oct 14
BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek (WSE:BML) Seems To Use Debt Quite Sensibly

More Unpleasant Surprises Could Be In Store For BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A.'s (WSE:BML) Shares After Tumbling 48%

Nov 29
More Unpleasant Surprises Could Be In Store For BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A.'s (WSE:BML) Shares After Tumbling 48%

We Think You Should Be Aware Of Some Concerning Factors In BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek's (WSE:BML) Earnings

Nov 16
We Think You Should Be Aware Of Some Concerning Factors In BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek's (WSE:BML) Earnings

Does BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek (WSE:BML) Deserve A Spot On Your Watchlist?

May 02
Does BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek (WSE:BML) Deserve A Spot On Your Watchlist?

Is BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek (WSE:BML) A Risky Investment?

Mar 08
Is BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek (WSE:BML) A Risky Investment?

What Percentage Of BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A. (WSE:BML) Shares Do Insiders Own?

Jan 29
What Percentage Of BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A. (WSE:BML) Shares Do Insiders Own?

Should Weakness in BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A.'s (WSE:BML) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials?

Jan 03
Should Weakness in BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A.'s (WSE:BML) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials?

BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek (WSE:BML) Takes On Some Risk With Its Use Of Debt

Dec 07
BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek (WSE:BML) Takes On Some Risk With Its Use Of Debt

Geschäftsführer

Mieczyslaw Starkowicz

2.3yrs

Amtszeit

Mr. Mieczyslaw Starkowicz serves as President of the Management Board and Chief Executive Officer at Synthaverse S.A. (formerly known as BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A.) since August 202...

Vorstandsmitglieder

NamePositionAmtszeitVergütungEigentümerschaft
Waldemar Sierocki
Secretary of Supervisory Board & Member of Supervisory Boardno datazł24.00k6.48%
PLN 19.9m
Konrad Miterski
Member of the Supervisory Boardno datazł42.00k0.072%
PLN 221.3k
Wiktor Napióra
Vice Chairman of the Supervisory Boardno datazł40.00k7.2%
PLN 22.1m
Dariusz Kucowicz
Member of Supervisory Board16.8yrszł39.00k0.31%
PLN 937.6k
Maciej Korniluk
Member of Supervisory Board1.8yrskeine Datenkeine Daten
Jaroslaw Blaszczak
Chairman of the Supervisory Boardno datazł113.00k2%
PLN 6.2m
Dirk Pamperin
Member of the Supervisory Board4.8yrszł37.00kkeine Daten
Maciej Siedlar
Member of Supervisory Board1.8yrskeine Daten0.14%
PLN 437.8k

3.3yrs

Durchschnittliche Betriebszugehörigkeit

Erfahrener Vorstand: SVEDie Vorstandsmitglieder gelten als erfahren (3.3 Jahre durchschnittliche Amtszeit).